{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:12:06Z","timestamp":1793502726123,"version":"4.5.0"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"DOI":"10.3389\/fgene.2020.578011","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T01:50:36Z","timestamp":1599789036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":172,"title":["Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials"],"prefix":"10.3389","volume":"11","author":[{"given":"Lourdes","family":"Hontecillas-Prieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Flores-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"de \u00c1lava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Hajji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Garc\u00eda-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1517\/14728221003796609","article-title":"Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin\u2019s lymphoma.","volume":"14","author":"Adams","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/jco.2016.70.5350","article-title":"Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignancies.","volume":"35","author":"Aggarwal","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B3","first-page":"49","article-title":"A novel Sirtuin-3 inhibitor, LC-0296, inhibits cell survival and proliferation, and promotes apoptosis of head and neck cancer cells.","volume":"36","author":"Alhazzazi","year":"2016","journal-title":"Anticancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1158\/1078-0432.ccr-14-3068","article-title":"Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma.","volume":"21","author":"Amengual","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1158\/1078-0432.ccr-16-2022","article-title":"Mechanisms of acquired drug resistance to the HDAC6 selective inhibitor ricolinostat reveals rational drug-drug combination with ibrutinib.","volume":"23","author":"Amengual","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3892\/ijo.2015.3240","article-title":"Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.","volume":"48","author":"Asgar","year":"2016","journal-title":"Int. J. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/sj.bjc.6603384","article-title":"Altered sirtuin expression is associated with node-positive breast cancer.","volume":"95","author":"Ashraf","year":"2006","journal-title":"Br. J. Cancer"},{"key":"B8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/CAD.0000000000000596","article-title":"Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.","volume":"29","author":"Balasubramaniam","year":"2018","journal-title":"Anticancer Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092241","article-title":"Immunoepigenetics combination therapies: an overview of the role of HDACs in cancer immunotherapy.","volume":"20","author":"Banik","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome \u2013 biological and translational implications.","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41416-018-0025-x","article-title":"DNMTi\/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.","volume":"118","author":"Bruyer","year":"2018","journal-title":"Br. J. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/modpathol.2017.125","article-title":"Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.","volume":"31","author":"Chaiyawat","year":"2018","journal-title":"Mod. Pathol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.radonc.2016.04.013","article-title":"Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.","volume":"119","author":"Chan","year":"2016","journal-title":"Radiother. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/j.1349-7006.2001.tb02153.x","article-title":"Expression profile of histone deacetylase 1 in gastric cancer tissues.","volume":"92","author":"Choi","year":"2001","journal-title":"Jpn. J. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10495-017-1364-4","article-title":"Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.","volume":"22","author":"Cosenza","year":"2017","journal-title":"Apoptosis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1038\/sj.onc.1210178","article-title":"Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.","volume":"26","author":"Cras","year":"2007","journal-title":"Oncogene"},{"key":"B18","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/1535-7163.mct-18-1068","article-title":"HDAC3 inhibition upregulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy.","volume":"18","author":"Deng","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1002\/ijc.27876","article-title":"HDAC11 is a novel drug target in carcinomas.","volume":"132","author":"Deubzer","year":"2013","journal-title":"Int. J. Cancer"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-018-0026-x","article-title":"Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma.","volume":"7","author":"Di Martile","year":"2018","journal-title":"Oncogenesis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1158\/1078-0432.ccr-14-3240","article-title":"Phase I study of vorinostat as a radiation sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma.","volume":"21","author":"DuBois","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.","volume":"66","author":"Duffy","year":"2017","journal-title":"J. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs.","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/s1534-5807(02)00360-x","article-title":"The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation.","volume":"3","author":"Fajas","year":"2002","journal-title":"Dev. Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080657","article-title":"Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1158\/0008-5472.CAN-19-1302","article-title":"HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.","volume":"79","author":"Fukumoto","year":"2019","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02.","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/1078-0432.ccr-14-2820","article-title":"A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma.","volume":"21","author":"Galloway","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"31397","DOI":"10.18632\/oncotarget.25829","article-title":"The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma.","volume":"9","author":"Garcia-Dominguez","year":"2018","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7185","DOI":"10.1128\/mcb.18.12.7185","article-title":"Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.","volume":"18","author":"Gelmetti","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.lungcan.2015.10.008","article-title":"Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.","volume":"90","author":"Gerber","year":"2015","journal-title":"Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/mph.0000000000000868","article-title":"Epigenetic combination therapy for children with secondary myelodysplastic syndrome (MDS)\/Acute Myeloid Leukemia (AML) and concurrent solid tumor relapse.","volume":"39","author":"Glasser","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.4161\/cbt.7.10.6561","article-title":"HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.","volume":"7","author":"Godman","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1042\/bst0350012","article-title":"Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy.","volume":"35","author":"Goldberg","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"B36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7150\/jca.16655","article-title":"Histone deacetylase inhibitor SAHA as potential targeted therapy agent for larynx cancer cells.","volume":"8","author":"Grabarska","year":"2017","journal-title":"J. Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6623","DOI":"10.1158\/1078-0432.ccr-19-1305","article-title":"Phase I\/Ib study of pembrolizumab plus vorinostat in advanced\/metastatic non-small cell lung cancer.","volume":"25","author":"Gray","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/35901","article-title":"Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.","volume":"391","author":"Grignani","year":"1998","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1158\/1535-7163.mct-17-0011","article-title":"Radiosensitization in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity.","volume":"17","author":"Groselj","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/bjc.2013.21","article-title":"Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.","volume":"108","author":"Groselj","year":"2013","journal-title":"Br. J. Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med. Chem."},{"key":"B42","first-page":"2831","article-title":"Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.","volume":"6","author":"Gumbarewicz","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.18383\/j.tom.2018.00031","article-title":"Assessing treatment response of glioblastoma to an HDAC inhibitor using whole-brain spectroscopic MRI.","volume":"5","author":"Gurbani","year":"2019","journal-title":"Tomography"},{"key":"B44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy.","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/cncr.29229","article-title":"Paclitaxel\/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: a randomized, phase 2 trial.","volume":"121","author":"Hainsworth","year":"2015","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/bies.201600070","article-title":"Histone deacetylase inhibitors for cancer therapy: an evolutionarily ancient resistance response may explain their limited success.","volume":"38","author":"Halsall","year":"2016","journal-title":"Bioessays"},{"key":"B47","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.239","article-title":"Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.","volume":"8","author":"Haydn","year":"2017","journal-title":"Cell Death Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.18632\/oncotarget.23485","article-title":"Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.","volume":"9","author":"Heijkants","year":"2018","journal-title":"Oncotarget"},{"key":"B50","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B51","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3109\/10428194.2015.1075019","article-title":"Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.","volume":"57","author":"Holkova","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00249","article-title":"MPT0G413, a novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells.","volume":"9","author":"Huang","year":"2019","journal-title":"Front. Oncol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-014-0111-1","article-title":"Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model.","volume":"22","author":"Huang","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.exphem.2016.03.001","article-title":"Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: a preclinical study.","volume":"44","author":"Ji","year":"2016","journal-title":"Exp. Hematol."},{"key":"B55","first-page":"2402","article-title":"Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer.","volume":"8","author":"Ji","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"B56","first-page":"5872","article-title":"Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.","volume":"7","author":"Jin","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"B57","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0154-8","article-title":"Combining carfilzomib and panobinostat to treat relapsed\/refractory multiple myeloma: results of a multiple myeloma research consortium phase I study.","volume":"9","author":"Kaufman","year":"2019","journal-title":"Blood Cancer J."},{"key":"B58","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/86507","article-title":"Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.","volume":"7","author":"Kim","year":"2001","journal-title":"Nat. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"25844","DOI":"10.1074\/jbc.m112.348284","article-title":"Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.","volume":"287","author":"Kim","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B61","article-title":"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.","volume":"9","author":"Knox","year":"2019","journal-title":"Sci. Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/emboj.2008.51","article-title":"Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks.","volume":"27","author":"Knutson","year":"2008","journal-title":"EMBO J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1111\/jcmm.14194","article-title":"Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.","volume":"23","author":"Lee","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"B64","first-page":"844","article-title":"The HDAC6 inhibitor ACY1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.","volume":"53","author":"Lee","year":"2018","journal-title":"Int. J. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11523-015-0372-y","article-title":"Histone deacetylase inhibitors resensitize EGFR\/EGFRvIII-overexpressing, erlotinib-resistant glioblastoma cells to tyrosine kinase inhibition.","volume":"11","author":"Liffers","year":"2016","journal-title":"Target Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00262-018-2283-0","article-title":"Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.","volume":"68","author":"Llopiz","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/35042612","article-title":"Deacetylation of p53 modulates its effect on cell growth and apoptosis.","volume":"408","author":"Luo","year":"2000","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/15384047.2018.1480281","article-title":"Dichloroacetic acid (DCA) synergizes with the SIRT2 inhibitor Sirtinol and AGK2 to enhance anti-tumor efficacy in non-small cell lung cancer.","volume":"19","author":"Ma","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/onc.2012.153","article-title":"WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells.","volume":"32","author":"Mackintosh","year":"2013","journal-title":"Oncogene"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1158\/2159-8290.cd-17-0177","article-title":"mTOR and HDAC inhibitors converge on the TXNIP\/Thioredoxin pathway to cause catastrophic oxidative stress and regression of RAS-driven tumors.","volume":"7","author":"Malone","year":"2017","journal-title":"Cancer Discov."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041423","article-title":"Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington\u2019s disease.","volume":"7","author":"McFarland","year":"2012","journal-title":"PLoS One"},{"key":"B72","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bjh.13315","article-title":"Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.","volume":"169","author":"Mishima","year":"2015","journal-title":"Br. J. Haematol."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133259","article-title":"Comparison of radiosensitization by HDAC inhibitors CUDC-101 and SAHA in pancreatic cancer cells.","volume":"20","author":"Moertl","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08301.x","article-title":"Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.","volume":"150","author":"Moreno","year":"2010","journal-title":"Br. J. Haematol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"B76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-60409-4","article-title":"Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.","volume":"10","author":"Moufarrij","year":"2020","journal-title":"Sci. Rep."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/sj.bjc.6605293","article-title":"Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.","volume":"101","author":"Munster","year":"2009","journal-title":"Br. J. Cancer"},{"key":"B78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/abbs\/gmv116","article-title":"Targeting epigenetic regulations in cancer.","volume":"48","author":"Ning","year":"2016","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173507","article-title":"Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.","volume":"12","author":"North","year":"2017","journal-title":"PLoS One"},{"key":"B80","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1078-0432.ccr-08-0684","article-title":"Histone deacetylase 8 in neuroblastoma tumorigenesis.","volume":"15","author":"Oehme","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ijc.20395","article-title":"Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.","volume":"112","author":"Osada","year":"2004","journal-title":"Int. J. Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1369\/0022155413506582","article-title":"Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.","volume":"62","author":"Parbin","year":"2014","journal-title":"J. Histochem. Cytochem."},{"key":"B83","first-page":"1677","article-title":"Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer.","volume":"25","author":"Park","year":"2011","journal-title":"Oncol. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes.","volume":"52","author":"Park","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1158\/0008-5472.can-15-2249","article-title":"Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth.","volume":"76","author":"Pathania","year":"2016","journal-title":"Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/ajh.25010","article-title":"A phase I\/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806.","volume":"93","author":"Persky","year":"2018","journal-title":"Am. J. Hematol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110409","article-title":"Breaking down the contradictory roles of histone deacetylase SIRT1 in human breast cancer.","volume":"10","author":"Rifai","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/ng1773","article-title":"A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.","volume":"38","author":"Ropero","year":"2006","journal-title":"Nat. Genet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/cas.12585","article-title":"Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC\/PI3K dual inhibitors.","volume":"106","author":"Saijo","year":"2015","journal-title":"Cancer Sci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.gde.2012.02.008","article-title":"Cancer epigenomics: beyond genomics.","volume":"22","author":"Sandoval","year":"2012","journal-title":"Curr. Opin. Genet. Dev."},{"key":"B92","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1038\/onc.2016.142","article-title":"Mechanism and relevance of EWS\/FLI-mediated transcriptional repression in Ewing sarcoma.","volume":"35","author":"Sankar","year":"2016","journal-title":"Oncogene"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1158\/1078-0432.ccr-14-0072","article-title":"Reversible LSD1 inhibition interferes with global EWS\/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.","volume":"20","author":"Sankar","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv394","article-title":"Role of reactive oxygen species in the abrogation of oxaliplatin activity by cetuximab in colorectal cancer.","volume":"108","author":"Santoro","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"B95","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.1128\/mcb.23.21.7719-7731.2003","article-title":"Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition.","volume":"23","author":"Siddiqui","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"28021","DOI":"10.1074\/jbc.m113.498758","article-title":"Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression.","volume":"288","author":"Song","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1158\/0008-5472.can-06-4152","article-title":"Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.","volume":"67","author":"Stark","year":"2007","journal-title":"Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi.","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1158\/1078-0432.ccr-17-0947","article-title":"Replication stress leading to apoptosis within the S-phase contributes to synergism between Vorinostat and AZD1775 in HNSCC harboring high-risk TP53 mutation.","volume":"23","author":"Tanaka","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/2159-8290.cd-11-0181","article-title":"Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas.","volume":"1","author":"Taylor","year":"2011","journal-title":"Cancer Discov."},{"key":"B101","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s10637-018-0696-4","article-title":"A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.","volume":"37","author":"Teknos","year":"2019","journal-title":"Invest. New Drugs"},{"key":"B102","article-title":"Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.","volume":"36","author":"Terranova-Barberio","year":"","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"114156","DOI":"10.18632\/oncotarget.23169","article-title":"HDAC inhibition potentiates immunotherapy in triple negative breast cancer.","volume":"8","author":"Terranova-Barberio","year":"","journal-title":"Oncotarget"},{"key":"B104","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/circresaha.112.270462","article-title":"Enhanced angiogenic and cardiomyocyte differentiation capacity of epigenetically reprogrammed mouse and human endothelial progenitor cells augments their efficacy for ischemic myocardial repair.","volume":"111","author":"Thal","year":"2012","journal-title":"Circ. Res."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.49","article-title":"Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.","volume":"8","author":"Thole","year":"2017","journal-title":"Cell Death Dis."},{"key":"B106","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-018-0231-4","article-title":"Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.","volume":"16","author":"Vanaja","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"B107","doi-asserted-by":"publisher","first-page":"15064","DOI":"10.1073\/pnas.0404603101","article-title":"Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.","volume":"101","author":"Vannini","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B108","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2090271","article-title":"A phase I\/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas.","volume":"2016","author":"Vitfell-Rasmussen","year":"2016","journal-title":"Sarcoma"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.ccr-16-2526","article-title":"Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma.","volume":"23","author":"Vogl","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B110","article-title":"Role of HDACs in normal and malignant hematopoiesis.","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"B111","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/2326-6066.CIR-18-0875","article-title":"Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas.","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20153663","article-title":"Additive pharmacological interaction between cisplatin (CDDP) and histone deacetylase inhibitors (HDIs) in MDA-MB-231 triple negative breast cancer (TNBC) cells with altered Notch1 activity-an isobolographic analysis.","volume":"20","author":"Wawruszak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2174\/1871520619666190114160457","article-title":"Nicotinamide overcomes doxorubicin resistance of breast cancer cells through deregulating SIRT1\/Akt pathway.","volume":"19","author":"Wei","year":"2019","journal-title":"Anticancer Agents Med. Chem."},{"key":"B114","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/emboj.2009.317","article-title":"CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.","volume":"29","author":"Wickstrom","year":"2010","journal-title":"EMBO J."},{"key":"B115","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1007\/s10620-013-2867-7","article-title":"The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma.","volume":"58","author":"Wu","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00044","article-title":"Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication.","volume":"4","author":"Xu","year":"2013","journal-title":"Front. Pharmacol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/s1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.leukres.2017.01.025","article-title":"Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.","volume":"56","author":"Zhang","year":"","journal-title":"Leuk. Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.3892\/mmr.2017.6290","article-title":"Role of histone deacetylase expression levels and activity in the inflammatory responses of patients with chronic hepatitis B.","volume":"15","author":"Zhang","year":"","journal-title":"Mol. Med. Rep."},{"key":"B120","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.18632\/oncotarget.3268","article-title":"Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s10637-015-0261-3","article-title":"Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.","volume":"33","author":"Zibelman","year":"2015","journal-title":"Invest. New Drugs"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fgene.2020.578011\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T16:34:34Z","timestamp":1668702874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fgene.2020.578011\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":121,"alternative-id":["10.3389\/fgene.2020.578011"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2020.578011","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"article-number":"578011"}}